Skip to main content
. 2024 Oct 17;13:e60270. doi: 10.2196/60270

Table 1.

Data collection summary by study visit.

Study phase Hospital or homea Hospital or homea Home-based assessments
Time-point description Screening visita (V1) Check-in visita (V2) Baseline visita (V3) Follow-up visita (V4) 12-week follow-up visit (V5)
Week –8 to 0 weeks –2 to 0 weeks 0 week 1 to 12 weeks 12 weeks
(V5: –3 to + 7 days)
Method of the visits In-person In-person Zoom call Weekly call Zoom call
Consent, review of inclusion or exclusion criteria a



Demographic and contact information a



Medical history review a



Medication inventory a

Release of medical records authorizations form a



Depression questionnaire using CES-Db a



Short physical performance battery test a



Pregnancy test

c
Randomization



Distribute TheraBand



Distribute or collect tablets and pre-addressed return package


Update of medical history


MOCA/BLINDd


Quality of life questionnaire—EQ-5D-5L version (via app)


Timed up and go (via app)


30 second sit to stand test (via app)




4 stage balance test (via app)




Collection of adverse experiences a
ECOGe/WHOf/Zubrod Scale


aScreening visit (V1) and check-in visit (V2) may be scheduled on the same day for those patients recruited after hospital discharge.

bCES-D: Center for Epidemiologic Studies Depression Scale.

cWe will send urine pregnancy tests every month for participants to complete at home. Pregnancy status will also be reassessed during the weekly calls.

dMOCA/Blind: Montreal Cognitive Assessment.

eECOG: Eastern Cooperative Oncology Group.

fWHO: World Health Organization.